KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Income: 2018-2025

Historic Net Income for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Net Income fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Net Income of -$32.0 million as of Q3 2025, which was down 139.04% from -$13.4 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Net Income registered a high of $58.2 million during Q1 2024, and its lowest value of -$90.9 million during Q1 2021.
  • Over the past 3 years, Esperion Therapeutics' median Net Income value was -$32.0 million (recorded in 2025), while the average stood at -$27.8 million.
  • Its Net Income has fluctuated over the past 5 years, first spiked by 192.46% in 2024, then tumbled by 171.30% in 2025.
  • Esperion Therapeutics' Net Income (Quarterly) stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then declined by 1.02% to -$57.4 million in 2023, then skyrocketed by 63.71% to -$20.8 million in 2024, then dropped by 2.90% to -$32.0 million in 2025.
  • Its Net Income stands at -$32.0 million for Q3 2025, versus -$13.4 million for Q2 2025 and -$41.5 million for Q1 2025.